Description: TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts
Home Page: www.transcodetherapeutics.com
RNAZ Technical Analysis
6 Liberty Square
Boston,
MA
02109
United States
Phone:
857-837-3099
Officers
| Name | Title |
|---|---|
| Mr. Robert Michael Dudley | Co-Founder, CEO, Pres & Director |
| Mr. Thomas A. Fitzgerald M.B.A. | CFO, VP of Admin. & Director |
| Dr. Zdravka Medarova Ph.D. | Co-Founder & CTO |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board |
| Dr. Qiyong Peter Liu Ph.D. | VP of R&D and Chief Scientist |
| Mr. Alan Freidman | VP of Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7189 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |